IRulya Therapeutics is a biotech company developing treatments for uncommon and serious genetic disorders. Its primary candidate, eDSP, is currently in Phase 3 testing for rare pediatric neurological diseases, particularly ataxia-telangiectasia, a genetic condition affecting the nervous system and immune function. The company uses a proprietary technology platform called AIDE that combines drug and device components to deliver medications by encapsulating them into a patient's own red blood cells using specialized automated equipment.

entry readiness 20 · NOT READY · exit proximity 53

Value area 23.47–41.41 · 5% of 120d volume overhead · clean runway